ME00261B - Tweak vezujuća antitijela - Google Patents

Tweak vezujuća antitijela

Info

Publication number
ME00261B
ME00261B MEP-2008-354A MEP2008354A ME00261B ME 00261 B ME00261 B ME 00261B ME P2008354 A MEP2008354 A ME P2008354A ME 00261 B ME00261 B ME 00261B
Authority
ME
Montenegro
Prior art keywords
binding antibodies
tweak binding
tweak
antibodies
tweak antibodies
Prior art date
Application number
MEP-2008-354A
Other languages
English (en)
Inventor
Linda C Burkly
Ellen Garber
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ME00261B publication Critical patent/ME00261B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Opisana su anti-tweak antitijela.
MEP-2008-354A 2005-05-27 2006-05-25 Tweak vezujuća antitijela ME00261B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68514905P 2005-05-27 2005-05-27
PCT/US2006/019706 WO2006130374A2 (en) 2005-05-27 2006-05-25 Tweak binding antibodies

Publications (1)

Publication Number Publication Date
ME00261B true ME00261B (me) 2011-02-10

Family

ID=37482143

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-354/08A MEP35408A (en) 2005-05-27 2006-05-25 Tweak binding antibodies
MEP-2008-354A ME00261B (me) 2005-05-27 2006-05-25 Tweak vezujuća antitijela

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-354/08A MEP35408A (en) 2005-05-27 2006-05-25 Tweak binding antibodies

Country Status (30)

Country Link
US (2) US8048422B2 (me)
EP (3) EP2460832A3 (me)
JP (4) JP5175181B2 (me)
KR (2) KR20080023317A (me)
CN (3) CN102441163A (me)
AU (1) AU2006252830B2 (me)
BR (1) BRPI0611414B8 (me)
CA (1) CA2609600C (me)
CY (1) CY1118343T1 (me)
DK (2) DK2460831T3 (me)
EA (1) EA018255B1 (me)
ES (2) ES2507069T3 (me)
GE (1) GEP20115324B (me)
HK (3) HK1116423A1 (me)
HU (1) HUE030701T2 (me)
IL (1) IL187585A (me)
IS (1) IS8693A (me)
LT (1) LT2460831T (me)
ME (2) MEP35408A (me)
MX (1) MX339015B (me)
NO (1) NO20076607L (me)
NZ (2) NZ564092A (me)
PL (3) PL1888113T3 (me)
PT (2) PT1888113E (me)
RS (1) RS55888B1 (me)
SG (1) SG162728A1 (me)
SI (2) SI2460831T1 (me)
UA (1) UA96416C2 (me)
WO (1) WO2006130374A2 (me)
ZA (1) ZA200710765B (me)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
KR20010102978A (ko) * 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
EP1811838A4 (en) * 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
US8685741B1 (en) * 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
CA2803392A1 (en) * 2010-06-24 2011-12-29 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
WO2015051234A2 (en) 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
MA54070A (fr) 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
US20210388096A1 (en) * 2018-10-31 2021-12-16 Astellas Pharma Inc. ANTI-HUMAN Fn14 ANTIBODY
CN112778372A (zh) 2019-11-11 2021-05-11 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
TW202302648A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 Cd79b抗體於自體免疫治療應用之用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AT396939B (de) * 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
DK0956351T3 (da) 1996-08-07 2006-02-20 Biogen Idec Inc Tumornekrosefaktorbeslægtet ligand
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
EP0977887A2 (en) 1997-02-12 2000-02-09 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
JP2001522584A (ja) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Ａｐｏ−３リガンドポリペプチド
AU6425699A (en) * 1998-10-16 2000-05-08 Cornell Research Foundation Inc. Methods of inhibiting platelet activation and recruitment
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
KR20010102978A (ko) * 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU5951901A (en) * 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1430666B1 (en) 2001-09-27 2005-08-31 Matsushita Electric Industrial Co., Ltd. Transmission method, sending device and receiving device
SI1997512T1 (sl) * 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
DE602004006871T2 (de) * 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US20090124993A1 (en) * 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
AU2006220825A1 (en) 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating TWEAK and FN14 activity
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis

Also Published As

Publication number Publication date
MX339015B (es) 2016-05-09
AU2006252830A1 (en) 2006-12-07
BRPI0611414A2 (pt) 2010-09-08
IL187585A (en) 2012-02-29
MEP35408A (en) 2011-02-10
EP1888113B1 (en) 2014-06-25
JP6234535B2 (ja) 2017-11-22
EA200702643A1 (ru) 2008-04-28
KR20080023317A (ko) 2008-03-13
KR101679468B1 (ko) 2016-11-24
US20080241163A1 (en) 2008-10-02
AU2006252830B2 (en) 2012-11-22
RS55888B1 (sr) 2017-08-31
US8048422B2 (en) 2011-11-01
UA96416C2 (uk) 2011-11-10
PL2460831T3 (pl) 2017-05-31
HUE030701T2 (hu) 2017-05-29
CA2609600A1 (en) 2006-12-07
HK1169418A1 (zh) 2013-01-25
DK2460831T3 (en) 2016-12-19
KR20130140230A (ko) 2013-12-23
DK1888113T3 (da) 2014-09-01
ES2605945T3 (es) 2017-03-17
ZA200710765B (en) 2009-09-30
EP1888113A4 (en) 2009-07-22
JP2017025105A (ja) 2017-02-02
NZ564092A (en) 2010-05-28
RS20070462A (en) 2008-11-28
PL218791B1 (pl) 2015-01-30
NZ583636A (en) 2011-12-22
WO2006130374A3 (en) 2007-12-13
PT1888113E (pt) 2014-09-04
JP2014221837A (ja) 2014-11-27
US20120009178A1 (en) 2012-01-12
BRPI0611414B1 (pt) 2019-04-16
SG162728A1 (en) 2010-07-29
WO2006130374A2 (en) 2006-12-07
SI1888113T1 (sl) 2014-10-30
EP2460831B1 (en) 2016-10-19
CN103242447A (zh) 2013-08-14
NO20076607L (no) 2008-02-27
JP5175181B2 (ja) 2013-04-03
HK1121072A1 (en) 2009-04-17
SI2460831T1 (sl) 2017-01-31
IS8693A (is) 2007-11-29
PT2460831T (pt) 2017-01-17
BRPI0611414B8 (pt) 2021-05-25
CN101247830A (zh) 2008-08-20
EP2460831A2 (en) 2012-06-06
CA2609600C (en) 2016-11-08
PL1888113T3 (pl) 2014-11-28
ES2507069T3 (es) 2014-10-14
HK1116423A1 (en) 2008-12-24
EP1888113A2 (en) 2008-02-20
EP2460832A2 (en) 2012-06-06
CN101247830B (zh) 2013-03-27
EA018255B1 (ru) 2013-06-28
JP2008542278A (ja) 2008-11-27
CN103242447B (zh) 2016-04-27
JP2013040210A (ja) 2013-02-28
EP2460832A3 (en) 2012-10-31
LT2460831T (lt) 2016-12-12
CN102441163A (zh) 2012-05-09
EP2460831A3 (en) 2012-10-31
CY1118343T1 (el) 2017-06-28
IL187585A0 (en) 2008-04-13
GEP20115324B (en) 2011-11-10

Similar Documents

Publication Publication Date Title
MEP35408A (en) Tweak binding antibodies
CY2019041I2 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
LTPA2016026I1 (lt) Anti-il-17 antikūnai
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DK1964852T3 (da) Anti-ilt7-antistof
DK3332808T3 (da) Humaniserede L243-antistoffer
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
ATE483732T1 (de) Madcam-antikörper
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20071430L (no) Anti-OX4OL antistoffer
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
HK1202299A1 (en) Novel cancer-associated antigen
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20052107D0 (no) Rep.
CY1115531T1 (el) Αντισωματα συνδεσης tweak
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
TR201105080T2 (tr) Özet başlığı bulunamadı.
ES1060051Y (es) Lampara.
NO20053273D0 (no) Rheometer.
ITMO20050300A1 (it) Elettrotermopergamena -- e.t.p.
ES1061845Y (es) Tiras correctoras.
ITPA20050006A1 (it) Sigaretta ecologica.
ES1061250Y (es) Conjunto garrafa-tapon.